AbbVie Has High Hopes for ImmunoGens Elahere | ABBV Message Board Posts


ABBV   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  719 of 729  at  11/30/2023 12:56:17 PM  by

jerrykrause


AbbVie Has High Hopes for ImmunoGens Elahere

AbbVie Has High Hopes for ImmunoGens Elahere -- Market Talk
 
Dow Jones
 
AbbVie says ImmunoGen's Elahere cancer therapy is a derisked asset that represents the most substantial component of its $10 billion deal value. ImmunoGen generated more than $105 million 3Q sales for Elahere, which won FDA approval late last year for platinum-resistant ovarian cancer.
 
AbbVie says Elahere's rapid uptake and strong launch trajectory in its first year represents one of the most successful new product launches in oncology. AbbVie says it expects Elahere sales to grow steadily in its initial indication and to begin rising significantly in 2030 and beyond following development in larger segments of the ovarian cancer market.
 
AbbVie notes the deal ascribes modest value to the rest of ImmunoGen's pipeline given early stages of development. AbbVie rises 1% to $139.78; ImmunoGen rockets 80% to $29.04. 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...